Summary
Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries.
Objectives:
To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App.
Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach.
Results: A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data.
About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users.
Conclusion and clinical relevance:
Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.
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| INTRODUCTION
Globally, non-adherence to medications is a major obstacle to the effective delivery of health care. Medication adherence and medication persistence are two different constructs. Medication adherence is defined as an active, cooperative and voluntary participation of the patient on following recommendations from a healthcare provider. This is a multifactorial behaviour that involves three critical steps, including initiation, implementation and discontinuation. 1 Medication persistence refers to the act of continuing the treatment for the prescribed duration. 2 In research employing electronic databases in pharmacies, primary adherence assesses whether the patient received the first prescription whereas secondary adherence is an ongoing process that measures whether the patient received dispensing or refills as prescribed during a defined observation period. 3 Medication persistence implies that the patient must have exhibited at least primary adherence, as it cannot be measured unless the patient has received the first dispensing. 3 The two most commonly-used secondary adherence medication measures are the Medication Possession Ratio (MPR) and the Proportion of Days Covered (PDC). 2 These two measures are closely related as they are both refill record-based adherence measurements.
Many mobile phone apps are available to support people in taking their medications and to therefore improve medication adherence. 4 ,5 However, a recent meta-analysis found that the majority did not have many of the desirable features and were of low quality. 4 It is known that adherence to treatment is low in allergic diseases and asthma. 6, 7 Mobile technology may help to better understand the adherence and its determinants as well how to improve adherence to treatment. 8 The aim of this study was to assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App.
| ME TH ODS

| Design of the study
An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Five visual analogue scales (VAS) assessed the daily control of the disease (i.e. global evaluation of allergic symptoms, nose, eyes, asthma and work). 16 Since users are anonymized and cannot be contacted, we could not use an adherence questionnaire such as the Morisky. 17, 18 The paper was written according to the STROBE checklist.
Inclusion criteria: people who had allergic rhinitis, who used the Allergy Diary, who completed at least 7 days (not necessarily consecutive) of symptom recording (VAS global score) and who continued to use the same AR medication over the study period.
| Setting
Users from 22 countries filled in the Allergy Diary (Table 4) . The
Allergy Diary is available in 16 languages (translated and back-translated, culturally adapted and legally complained).
| Users
All consecutive users who registered to the Allergy Diary were included if they had filled in the VAS global measured. The Allergy Diary is filled in independently from the presence/absence of symptoms. There were no exclusion criteria for participation in the Allergy Diary initiative. Basic demographic characteristics (age, sex, country and language) were recorded. The Allergy Diary was used by people who found it on the internet, Apple store, Google Play or in any other way. Some users were patients who were asked by their physicians to use the app. However, due to anonymization of data, specific information could not be gathered as previously described in detail. 12, 13 The diagnosis of allergic rhinitis is based on the question "I have allergic rhinitis" but all users had rhinitis symptoms.
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| Allergy Diary and outcomes
The Allergy Diary collects information on AR symptoms experienced (nasal and ocular), disease type (intermittent/persistent), how symptoms impact users' lives and type(s) of AR treatment used. Geolocalized users assess their daily symptom control via the touchscreen functionality on their smart phone: they click on five consecutive VAS measures (VAS global measured, VAS-nasal, VAS-ocular, VASasthma and VAS-work). Levels range from zero (not at all bothersome) to 100 (very bothersome). Independency of VAS questions was previously assessed using the Bland and Altman regression analysis. 13, 19 Users input their daily medications using a scroll list which contains all country-specific over the counter and prescribed medications available ( Figure S1 ). The list has been populated using IMS data.
Some of the VAS data used in this study have been analysed in other studies with a different aim including work productivity 12 and assessment of treatment or multimorbidity (papers submitted). Moreover, the time frame of the three other studies was different.
| Ethics
The Allergy Diary is CE1 registered. The terms of use have been translated into all languages and customized according to the legislation of each country. This thereby allows the use of the results for research purposes. The data are anonymized-including the geolocalized data-using k-anonymity. [20] [21] [22] An Independent Review Board approval was not needed for this observational study. However, using the Allergy Diary, MPR and PDC with the IPSOR terminology cannot be directly calculated using a classical method. 23 They can however be approached. In the present paper, we used:
• Proportion of medication possession ratio (modified MPR): ratio of days that medication was reported to be used on days in a given time interval (see definitions 2 and 3 for further details)
• Proportion of days covered over a time interval (modified PDC): ratio of days that medication was reported to be used on days in the time interval between the first and the last record considered (i.e.
the first and the last day on which the symptoms control VAS is filled in)
| Number of days with VAS reported
A cut-off of at least 7 records of VAS was set up to ensure an adequate amount of data assessing adherence. Therefore, only users matching this cut-off were included in the study.
| Predetermined time interval
The first 14 records were analysed since the duration of symptoms in AR is usually short 24 :
• In users who reported 7-14 days of data/symptom recording, we analysed the total number of days of recording.
• In users who reported over 14 days of data/symptom recording, only the first 14 were analysed.
• Data in duplicate (reporting, for the same day, two assessments) and multiplicate (reporting, for the same day, more than two assessments) have occurred (<10% of subjects). 
| Medication possession ratio (modified MPR)
We proposed that:
• The same rhinitis treatment should be used during the time interval. No change in treatment for rhinitis was accepted, and change represented an exclusion criteria. However, treatment for asthma was not considered and may vary.
• Based on an accepted adherence level ≥70%, the minimum number of days of data recording/collection was determined (Table 1 ).
• The modified MPR score was calculated as:
days of reported treatment time interval ðas determined by predetermined time intervalÞ () 2.6.5 | Proportion of days covered over a time
interval (modified PDC)
Both continuous and discontinuous/intermittent reporting was monitored/evaluated. We defined five levels of adherence depending on the modified PDC ( Table 2) • The first and last days of data recording were identified and defined the time interval.
• The dates of reporting within the time interval were assessed and counted.
• For duplicates or multiplicates, the number considered was the exact number (1, 2, 3…). • The modified PDC score was calculated as:
days of reporting time interval ðas determined by first and last day of useÞ ()
• A number of recorded days greater than the time interval considered indicates that the user is taking more drugs than the initial treatment. We used two levels of PDC ≤1.25 (adherent user to time interval as defined by first and last days of recording) and ≤1.5 (adherent or partly adherent user to time interval as defined by first and last day of recording). Combining PDC ≤1.25 or ≤1.5 with MPR values, four groups were defined (Table 3 ).
| Biases
In this study, we did not include the types of treatment used due to the significant variability between treatment recommendations in different countries and no clear pattern of treatment being easily identified from the data collected.
Although MASK can be used to assess medication adherence, 
| Sample size
In this exploratory study, all registered users who fulfilled the inclusion criteria over the study period were included in order to obtain the best possible estimates for the specified time window.
| Statistical analysis
For normally distributed data, means and SD were used.
| RESULTS
| Characteristics of the user
A total number of 12 143 users were registered in the Allergy Diary during the observational period. About 6 949 users reported at least one VAS data recording. A total of 64 566 VAS recordings were made. Among them, 1 887 users reported ≥7 VAS data ( Figure 1 ).
There were 888 (47%) males and 999 (53%) females. They had a median age of 32 years (25-75 percentiles: 22-44 years). The repartition of user by country is presented in Table 4 .
| Overall results
Overall results are presented in | 447 likely to be adherent. Moreover, the median level of time interval was different between groups, suggesting that discontinuous treatment is associated with poorer medication adherence.
| DISCUSSION
Our study was characterized by information retrieved from patients from 22 countries. To our knowledge, this is the first study to perform an evaluation of medication adherence based on data retrieved from a mobile app using a routine way/real-life setting. This study shows the very low adherence to treatment in AR patients in a reallife setting.
| Strengths and limitations
The strengths and limitations of this study are those of mobile technology, as previously discussed.
12,13,25 There are potential measurement biases when using apps since the information collected is usually restricted and less complete than when using more detailed paper or web-based questionnaires. App users may be a selected subset and therefore not fully representative of all AR patients.
Higher education or specific age ranges might apply. The study was not meant to be representative of the general population. Precise patient characterization is impossible via an App used in real life, but every observational study using the Allergy Diary gave highly consistent results with a clear clinical perspective. 11-13 Users self-reported the diagnosis of rhinitis but this was confirmed by the questionnaire on rhinitis and conjunctivitis symptoms included in the App. Mobile technology is likely to become an important tool to better understand and manage AR and asthma.
Other limitations should also be considered. Among a high number of users, only a relatively low number were constantly providing information on treatment in the app and we only considered users reporting over 6 days. We did not analyse the type of treatment due to its great variability. This will be done when more data become available and using machine learning approaches. Another limitation is that the app is based on the unsupervised input of data. There is, therefore, a bias related to potentially missing data input. Nevertheless, our study took the opportunity of analysing real-world adherence and designing new methodologies for analysing such data.
We did not include a questionnaire on medication adherence since users report their daily medications.
| Discussion of results
Our data show that about 70% of AR patients providing data over 6 days (27.2% of the entire database) are non-adherent to medications. Only 11.3% of AR users providing data over 6 days were fully adherent to medications and time interval (MPR ≥70% and PDC
≤1.25).
Few studies reported the prevalence of adherence in AR patients in the real-life context. About 35% of patients were non-adherent for some time during the treatment, and 38% indicated that they discontinued treatment when they felt better. 26, 27 One study, carried out in the outpatient setting, suggests that a short message service (SMS) helps to improve AR treatment. 28 Adherence in randomized control trials is high but does not reflect the real-life situation, 29,30 and alternative measurement of adherence in a real-life setting is needed. The best studies would be using electronic devices that count and record the drugs taken.
However, these devices are expensive and, as such, not a viable solution for large studies in AR patients. 31 Considering that we live in an era of "digital revolution" and that a huge percentage of people have a smartphone, mobile applications appeared as a good alternative to improve patient control over their illness. Such mobile health (m-health) technology has enormous potential to be used as a reliable, cost-effective and usable tool, not only for AR, but also for other diseases. 
| 449
There is no gold standard for measuring adherence to medication. There are mainly direct and indirect measures. All methods have their limitations, so it is highly recommended to combine more than one. 34 In this study, we used a combination of MPR and PDC, the most used measures of secondary adherence. We defined adherence as MPR ≥70% and PDC ≤1.25. Results were grouped by PDC value by using a cut-off value of 1.25. Therefore, the resulting groups had PDC ≤1.25 and PDC >1.25, respectively. It was possible to verify that, although with some differences, both follow the same trend. Under 15-20 days, patients were mostly non-adherent, and there are some theories that can explain this such as that for many patients, AR is only intermittent and that the most troublesome symptoms can be managed with a short course of medication. There are several subtypes of allergic rhinitis and, depending on the type and severity of the condition, the treatment may be different. AR can be described as a seasonal condition; therefore, some patients may present persistent symptoms while others may present symptoms only when the allergen is present. On the other hand, above 15 days of VAS reported, patients tend to be more adherent, which may also be a result of more severe symptoms, leading to continuous treatment 27, 35 or to a better adherence in people reporting longer periods of use. It would be important to also study the attitudinal and behavioural clusters of individuals who continue to monitor and treat their AR for more than 15 days. Insights from research in asthma suggest that determining attitudinal clusters can provide insights into medication use and taking behaviour. 36 All the participants were volunteers and anonymous, making them very remote from direct clinical input. Also, patients had no sense of being watched over (Hawthorn effect) which prevents a biased increase in adherence. In RCTs, adherence is likely to be much higher. 37 Further research is needed to understand how patients can be motivated to use an app regularly, and the role of the healthcare professional in suggesting that the app is used as a means of assisting the patient to better understand their disease, monitor their symptoms and promote adherence.
| CONCLUSION
This is the first paper to present adherence to AR treatment in a real-world setting from a European population sample. 
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Additional supporting information may be found online in the Supporting Information section at the end of the article. 
